References: | Duvic, M., Talpur, R., Ni, X., Zhang, C., Hazarika, P., Kelly, C., ... & Frankel, S. R. (2007). Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL).Blood,109(1), 31-39. Marks, P. A., & Breslow, R. (2007). Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug.Nature biotechnology,25(1), 84-90. Shankar, S., Davis, R., Singh, K. P., Kurzrock, R., Ross, D. D., & Srivastava, R. K. (2009). Suberoylanilide hydroxamic acid (Zolinza/vorinostat) sensitizes TRAIL-resistant breast cancer cells orthotopically implanted in BALB/c nude mice.Molecular cancer therapeutics,8(6), 1596-1605. |